SITC 2017 Downloadable Schedule

Pre-Conference Programs • Nov. 8-9

Immuno-Oncology Biomarkers: Today’s Imperatives for Tomorrow’s Needs
Nov. 8, 2017

2nd World Immunotherapy Council Young Investigator Symposium
Nov. 8, 2017

Primer on Tumor Immunology and Cancer Immunotherapy™
Nov. 9, 2017

Workshop on Single Cell Techniques in Immunology and Cancer Immunotherapy
Nov. 9, 2017

Meet-the-Expert Lunch
Nov. 9, 2017

Grant Writing Workshop
Nov. 9, 2017

32nd Annual Meeting • Nov. 10-12
Immuno-Oncology Biomarkers: Today’s Imperatives for Tomorrow’s Needs

**Wednesday, November 8, 2017**

*Cherry Blossom Ballroom*

8 – 8:15 a.m. **Welcome and Introductions**
Lisa H. Butterfield, PhD – *University of Pittsburgh*

**Session I: Biomarkers in Development**

**General Biomarkers**

8:15 – 8:25 a.m. **Immune Report Card**
Carl Morrison, MD, DVM – *OmniSeq, Inc.*

8:25 – 8:35 a.m. **Multiplex IHC Immuno-Oncology Panel for Standardized Profiling of the Immune Status Based on Spatial and Functional Characterization of the Tumor Microenvironment**
Svenja Lippok, PhD – *Definiens AG*

8:35 – 8:45 a.m. **Exosome Repertoires and Cargo Associated with Tumor Progression and Responses to Treatment**
Jennifer Jones, MD, PhD – *National Institutes of Health, National Cancer Institute, Center for Cancer Research*

8:45 – 8:55 a.m. **A Biomarker-Driven Approach for the Development of the ICOS Agonist Antibody, JTX-2011**
Heather A. Hirsch, PhD – *Jounce Therapeutics, Inc.*

8:55 – 9:10 a.m. **Group Discussion**

**Biomarkers Supporting Primarily Immune Checkpoint Blockade**

9:10 – 9:20 a.m. **Composite Predictors of Efficacy to Checkpoint Inhibitors and Mechanisms of Immune Escape, Informing Combination Strategies via Personalized Cancer Immunotherapy**
Priti S. Hedge, PhD – *Genentech*

9:20 – 9:30 a.m. **Pretreatment Gene Expression Correlation with Clinical Response to Pembrolizumab or Nivolumab in Metastatic Melanoma**
Tobias Scatton, PharmD, PhD – *Harvard Medical School & Brigham and Women’s Hospital*

9:30 – 9:40 a.m. **Calibration of FoundationOne® with Whole Exome Sequencing for Assessment of Tumor Mutation Burden as a Biomarker for Response to Immune Checkpoint Inhibitors**
Joseph D. Szustakowski, PhD – *Bristol-Meyers Squibb*

9:40 – 9:50 a.m. **Biomarkers for Primary Immunotherapy Resistance Based on the Circulating Proteome**
Heinrich Roder, PhD – *Biodesix Inc.*

9:50 – 10:05 a.m. **Group Discussion**

10:05 – 10:20 a.m. **Break**
Biomarkers Supporting Primarily T cell Interventions

10:20 – 10:30 a.m. Pharmacodynamic and Predictive Biomarkers Supporting Development of CAR T Cells for the Treatment of B cell Malignancies
John Rossi, MSc – Kite Pharma, Inc.

10:30 – 10:40 a.m. Single T cell Functional Response Biomarkers to Differentiate Responders and Non-Responders in CAR-T and Checkpoint Based cancer Immunotherapies
Jon Chen – Isoplexis

10:40 – 10:50 a.m. Standardized Immune-Based Diagnostic Tests to Predict the Risk of Recurrence and Response to Therapy of Cancer Patients
Fabienne Hermitte, PhD – HalioDx

10:50 – 11 a.m. Public NY-ESO-1 Specific TCRs as Novel Biomarkers for Immune Monitoring of NY-ESO-1 Positive Cancer Patients
Hailing Lu, MD, PhD – Immune Design

11 a.m. – 11:15 a.m. Group Discussion

11:15 – 11:30 a.m. Break

Session II: Strategic Considerations of Biomarkers

11:30 – 11:45 a.m. The Regulatory Perspective
Gideon Blumenthal, MD – Food & Drug Administration

11:45 – 12:25 p.m. Panel Discussion
Jerome Galon, PhD – INSERM- Cordeliers Research Center
Francesco Marincola, MD – AbbVie Inc.
Minkyung Song, PhD – National Cancer Institute, National Institute of Health

12:25 – 12:30 p.m. Closing Remarks

7 – 8 p.m. Networking Reception
Cherry Blossom Foyer
2nd World Immunotherapy Council Young Investigator Symposium

Wednesday, November 8, 2017
Cherry Blossom Ballroom

1 – 1:05 p.m.   Welcome and Introductions
Tanja de Gruijl, PhD – VU University Medical Center
Graham Pawelec, PhD – University of Tuebingen

Session I: Checkpoint Blockade

Senior Co-Chairs:
Beatrix Kotlan, PhD – National Institute of Oncology, Budapest
Sacha Gnjatic, PhD – Cancer Research Institute (CRI)
Zihai Li, MD, PhD – Chinese American Hematology Oncology Network (CAHON)
Lisa H. Butterfield, PhD – Society for Immunotherapy of Cancer (SITC)
Willemijn Hobo, PhD – Dutch Tumor Immunology Working Party (DTIWP)

1:05 – 1:10 p.m.   Junior Co-Chair Welcome
Hong Zheng, MD, PhD – Pennsylvania State Cancer Institute

1:10 – 1:25 p.m.   Immunotherapy - Long-Term Survival in Metastatic Melanoma
Katalin Czirbesz, MD – National Institute of Oncology, Budapest

1:25 – 1:40 p.m.   PD-1 Blockade: Understanding CD8 T Cell Rescue for Insights into Cancer Immunotherapy
Alice O. Kamphorst, PhD – Cancer Research Institute (CRI)

1:40 – 1:55 p.m.   Viral Based Cancer Immunotherapy in the Era of Immune Checkpoint Blockade
Liang Deng, MD, PhD – Chinese American Hematology Oncology Network (CAHON)

1:55 – 2:10 p.m.   Treg Modulation as a Pharmacodynamic Biomarker of GITR Stimulation in Cancer Patients
Roberta Zappasodi, PhD – Society for Immunotherapy of Cancer (SITC)

2:10 – 2:25 p.m.   PD-L1 Expression on Malignant Cells is no Prerequisite for Checkpoint Therapy
Jan Willem Kleinovink, MS – Dutch Tumor Immunology Working Party (DTIWP)

2:25 – 2:40 p.m.   Break

Session II: Adoptive T Cell Therapy

Senior Co-Chairs:
Robert E. Hawkins, MD, PhD – Adoptive Engineered T Cell Targeting to Activate Cancer Killing (ATTACK)
Per thor Straten, PhD – Progress in Vaccination Against Cancer (PIVAC)
Pamela Ohashi, PhD – Canadian Cancer Immunotherapy Consortium (CCIC)

2:40 – 2:45 p.m.   Junior Co-Chair Welcome
Marco Ruella, MD – University of Pennsylvania

2:45 – 3:00 p.m.   Exploiting Tumor Infiltrating Lymphocytes (TILs) as a Therapeutic Strategy for Epithelial Ovarian Cancer
Gemma Owens, MB, BCh – Adoptive Engineered T Cell Targeting to Activate Cancer Killing (ATTACK)
3:00 – 3:15 p.m.  Combined Killing of Cancer Cells and Cross Presentation of Tumor Antigens By Vy9Vδ2 T Cells
Gitte Holmen Olofsson, MS – Progress in Vaccination Against Cancer (PIVAC)

3:15 – 3:30 p.m.  A Novel Innate Lymphoid Cell Population Regulates Tumor – Associated T Cells
Sarah Crome, PhD – Canadian Cancer Immunotherapy Consortium (CCIC)

3:30 – 3:45 p.m.  Break

Session III: Innate Immunity

Senior Co-Chairs:
Weihua Xiao, MD, MS – Chinese Society of Immunology (CSI) and Committee for Tumor Immunology and Bio Therapy (TIBT)
Heinz Zwierzina, MD – Cancer Drug Development Forum (CCDF)
Angus Dalgleish, MD, PhD – Institute for Cancer Vaccines and Immunotherapy (ICVI)

3:45 – 3:50 p.m.  Junior Co-Chair Welcome
Cheng Sun, MD, PhD – Chinese Academy of Sciences and University of Science & Technology of China

3:50 – 4:05 p.m.  Dysfunction of Dendritic Cells in Lung Cancer
Fang Fang, PhD – Chinese Society of Immunology (CSI) and Committee for Tumor Immunology and Bio-Therapy (TIBT)

4:05 – 4:20 p.m.  Development of a Novel Immunotherapy with Toll-Like and Nod-Like Receptors Synergy for Targeted Cancer Therapy
Célia Jacobberger-Foissac, MSc – Cancer Drug Development Forum (CDDF)

4:20 – 4:35 p.m.  Zoledronic Acid Induces Gamma Delta T Cells to Target Macrophages
Daniel William Fowler, PhD – Institute for Cancer Vaccines and Immunotherapy (ICVI)

4:35 – 5:40 p.m.  Dinner Break

Session IV: Novel Approaches to Improve Immunotherapy

Senior Co-Chairs:
Kazuhiro Kakimi, MD, PhD – Japanese Association of Cancer Immunology (JACI)
Barbara Seliger, MD, PhD – Tumor Immunology Meets Oncology (TIMO)
Michele Maio, MD, PhD – NIBIT Foundation (Network Italiano per la Bioterapia dei Tumori)
Giuseppe Masucci, MD, PhD – Scandinavian Network for Immunotherapy of Cancer (SNIC)

5:40 – 5:45 p.m.  Junior Co-Chair Welcome
Margot Pont, PhD – Fred Hutchinson Cancer Research Center

5:45 – 6:00 p.m.  An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Cancer Immunotherapy
Takahiro Karasaki, MD – Japanese Association of Cancer Immunology (JACI)

6:00 – 6:15 p.m.  Reversing the Tumor Immune Escape with Selenium
Claudia Lennicke, PhD – Tumor Immunology Meets Oncology (TIMO)

6:15 – 6:30 p.m.  Epigenetic Immunomodelling to Improve the Efficacy of Cancer Immunotherapy
Alessia Covre, PhD – NIBIT Foundation (Network Italiano per la Bioterapia dei Tumori)

6:30 – 6:45 p.m.  Blood in Circulation, with Intact Cascade Systems, as a Tool to Predict First-Infusion Reactions and Mechanism of - Action of Immunotherapeutics
Erika Fletcher, PhD – Scandinavian Network for Immunotherapy of Cancer (SNIC)
6:45 – 7 p.m. **Closing Remarks**
Graham Pawelec, PhD – University of Tuebingen

7 – 8 p.m. **Networking Reception**
Cherry Blossom Foyer
Primer on Tumor Immunology and Cancer Immunotherapy™

Thursday, November 9, 2017
Maryland Ballroom C

8 – 8:05 a.m.  Welcome and Introductions
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai

Session I: Basic Immunology – A Brief Overview

8:05 – 8:35 a.m.  Innate Lymphocytes
Amir Horowitz, PhD – Icahn School of Medicine at Mount Sinai

8:35 – 9:05 a.m.  Monocytes and Macrophages in Cancer
Vincenzo Bronte, MD – University of Verona

9:05 – 9:35 a.m.  Dendritic Cells and Antigen
A. Karolina Palucka, MD, PhD – The Jackson Laboratory for Genomic Medicine

9:35 – 10:05 a.m.  Adaptive Immunity
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

10:05 – 10:20 a.m.  Panel Questions and Answers
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai

10:20 – 10:35 a.m.  Break

Session II: Treating Tumors with Passive Immunotherapy

10:35 – 10:40 a.m.  Session II Introduction
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai

10:40 – 11:10 a.m.  Cytokines: Interferons, Interleukins and Beyond
Jeffrey S. Miller, MD – University of Minnesota

11:10 – 11:40 a.m.  Adoptive T Cell Therapy
Cassian Yee, MD – University of Texas MD Anderson Cancer Center

11:40 – 12:10 p.m.  Monoclonal Antibodies and Bi-Specifics/Structure and Mechanism of Action
Charles G. Drake, MD, PhD – Columbia University Medical Center

12:10 – 12:25 p.m.  Panel Questions and Answers
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at The Mount Sinai Medical Center

12:30 – 1:30 p.m.  Lunch

Session III: Active Immunotherapy: Unleashing the Patient’s Own Immune System

1:30 – 1:35 p.m.  Session III Introduction
Timothy NJ Bullock, PhD – University of Virginia
1:35 – 2:05 p.m.  
Targeting Regulatory Molecules in Cancer Therapy: New Insights and Opportunities  
Michael A. Curran, PhD – University of Texas MD Anderson Cancer Center

2:05 – 2:35 p.m.  
Cancer Vaccines  
Ross Kedl, PhD – University of Colorado School of Medicine

2:35 – 2:50 p.m.  
Panel Questions and Answers  
Timothy NJ Bullock, PhD – University of Virginia

2:50 – 3:05 p.m.  
Break

Session IV: Immune Monitoring: Figuring Out How it All Works

3:05 – 3:10 p.m.  
Session IV Introduction  
Timothy NJ Bullock, PhD – University of Virginia

3:10 – 3:40 p.m.  
Immune Monitoring and Next Generation  
Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai

3:40 – 4:10 p.m.  
On The Horizon: IO Combinations  
Jeffrey Sosman, MD – Northwestern University

4:10 – 4:40 p.m.  
Biomarkers – Mutational Load  
Timothy A. Chan, MD, PhD – Memorial Sloan Kettering Cancer Center

4:40 – 4:55 p.m.  
Panel Questions and Answers  
Timothy NJ Bullock, PhD – University of Virginia

4:55 – 5 p.m.  
Closing Remarks  
Timothy NJ Bullock, PhD – University of Virginia
Workshop on Single Cell Techniques in Immunology and Cancer Immunotherapy

**Thursday, November 9, 2017**
*Maryland Ballroom A*

8 – 8:05 a.m.  **Welcome and Introductions**
Nicholas McGranahan, PhD – University College London

**Session I: Tumor Heterogeneity and Evolution under Immune Pressure and Treatment**
*Chair: Nicholas McGranahan, PhD – University College London*

8:05 – 8:30 a.m.  **T Cell Plasticity and Cancer Immunoediting**
Charles Swanton, MD, PhD, FRCP – University College London

8:30 – 8:55 a.m.  **Tumor Neoantigens and Presentation and Recognition**
James R. Heath, PhD – California Institute of Technology

8:55 – 9:20 a.m.  **Evolution of Neoantigen Landscapes**
Valasmo Anagnostou, MD, PhD – Johns Hopkins University

9:20 – 9:45 a.m.  **Break**

**Session II: Tumor Immune Microenvironment**
*Chair: Gordon J. Freeman, PhD – Dana Farber Cancer Institute*

9:45 – 10:10 a.m.  **T cell Differentiation in the Tumor Microenvironment**
Ana C. Anderson, PhD – Harvard Medical School

10:10 – 10:35 a.m.  **Analysis of Human Anti-Tumor Immune Responses**
Nir Hacohen, PhD – Massachusetts General Hospital

10:35 – 11 a.m.  **Myeloid Cells in Lung Tumors Using CyTOF**
Miriam Merad, MD, PhD – Icahn School of Medicine at Mount Sinai

11 – 11:25 p.m.  **Computational Methods for Analyzing Single Cells in the Tumor Microenvironment**
Dana Pe’er, PhD – Memorial Sloan Kettering Cancer Center

11:25 – 11:50 a.m.  **Methods and Applications of Single Cell Genomics**
Rahul Satija, PhD – New York Genome Center

11:50 a.m. – 12:15 p.m.  **Mass Spectrometry and Basic Spatial Imaging Methods of Tissues**
Michael Angelo, MD, PhD – Stanford University

12:15 – 1 p.m.  **Lunch**

**Session III: Predictor Response & Liquid Biopsy**
*Chair: Gordon J. Freeman, PhD – Dana Farber Cancer Institute*

1 – 1:25 p.m.  **PDL1 Response**
Priti Hegde, PhD – Genentech

1:25 – 1:50 p.m.  **Pre & Post PD1**
Sean Mackay – IsoPlexis
1:50 – 2:15 p.m.  Analysis of Circulating Tumor DNA/Tumor Cells  
Abhijit Patel, MD, PhD – Yale University School of Medicine

2:15 – 2:40 p.m.  Influence of Gut Microbiome upon PD1/I-O Responses  
Jennifer A. Wargo, MD, MMSc – University of Texas MD Anderson Cancer Center

2:40 – 3:05 p.m.  Break

**Session IV: How to Apply Single Cell to Your Research**

*Chair: Nir Hacohen, PhD – Massachusetts General Hospital*

3:05 – 4:05 p.m.  Discussion on Experimental and Computational Methods  
Alexandra-Chloé Villani, PhD – Broad Institute of Massachusetts Institute of Technology

4:05 – 4:55 p.m.  Panel Discussion  
Nir Hacohen, PhD – Massachusetts General Hospital

4:55 – 5 p.m.  Closing Remarks  
Nir Hacohen, PhD – Massachusetts General Hospital
Meet-the-Expert Lunch

**Thursday, November 9, 2017**
*Chesapeake JKL*

12:30 – 12:35 p.m. **Welcome**
Davide Bedognetti, MD, PhD – *Sidra Medical and Research Center*

12:35 – 1:20 p.m. **Publishing Papers**
Susan Kaech, PhD – *Yale University*

12:35 – 1:20 p.m. **Networking and Developing Successful Collaborations**
Jennifer Wargo, MD, MMSC – *University of Texas MD Anderson Cancer Center*

12:35 – 1:20 p.m. **Basic-Translational Research**
Nir Hacohen, PhD – *Massachusetts General Hospital*

12:35 – 1:20 p.m. **Clinical-Translational Research**
Mario Sznol, MD – *Yale Cancer Center*

12:35 – 1:20 p.m. **Career Path: Alternative Careers – Science Policy, Funding Advocacy and Project Management**
Howard L. Kaufman, MD, FACS – *Replimune Group, Inc.*

12:35 – 1:20 p.m. **Career Path: The Big Pharma Industry Perspective**
Kimberly Shafer-Weaver – *AstraZeneca, LP*

12:35 – 1:20 p.m. **Career Path: The Small Biotech Industry Perspective**
Alessandra Cesano, MD, PhD – *NanoString Inc.*

12:35 – 1:20 p.m. **Career Path: How to Kick-Start Your Career in the US – An International Perspective**
Sandra Demaria, MD – *Weill Cornell Medical College*

12:35 – 1:20 p.m. **Career Path: How to Survive in Academia**
Jonathan Powell, MD, PhD – *Johns Hopkins University School of Medicine*

12:35 – 1:20 p.m. **Career Path: How to Navigate the Postdoc to PI Transition**
Matthew Gubin – *Washington University School of Medicine*

1:20 – 1:30 p.m. **Networking Time**
# Grant Writing Workshop

**Thursday, November 9, 2017**

## Session I: Introduction to Grant Writing

*Chesapeake DE*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m.</td>
<td>Welcome and Overview of Grant Writing Workshop</td>
<td>Lorenzo Falchi, MD</td>
<td><em>Columbia University Medical Center</em></td>
</tr>
<tr>
<td>1:35 p.m.</td>
<td>Introductions</td>
<td>Marco Ruella, MD</td>
<td><em>University of Pennsylvania</em></td>
</tr>
<tr>
<td>1:40 p.m.</td>
<td>Identifying and Selecting the Right Grant</td>
<td>Sandra Demaria, MD</td>
<td><em>Weill Cornell Medical College</em></td>
</tr>
<tr>
<td>2:05 p.m.</td>
<td>Mechanics of Grant Writing</td>
<td>John Barrett, MD</td>
<td><em>National Heart, Lung, and Blood Institute</em></td>
</tr>
<tr>
<td>2:30 p.m.</td>
<td>Panel Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:45 p.m.</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Session II: Mechanisms of Grant Review

### Track A: Career Development Awards

*Chesapeake DE*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 p.m.</td>
<td>Welcome and Introductions</td>
<td>Jennifer Guerriero, PhD</td>
<td><em>Dana-Farber Cancer Institute</em></td>
</tr>
<tr>
<td>3:05 p.m.</td>
<td>Overview of Awards from Foundations and Societies</td>
<td>Kim A. Margolin, MD</td>
<td><em>City of Hope</em></td>
</tr>
<tr>
<td>3:35 p.m.</td>
<td>Overview of NIH Transition Grants</td>
<td>Sonia Jakowlew, PhD</td>
<td><em>National Institutes of Health</em></td>
</tr>
<tr>
<td>4:05 p.m.</td>
<td>Guided Tour of NIH Peer Review Process</td>
<td>Sergei Radaev, PhD</td>
<td><em>National Institutes of Health</em></td>
</tr>
<tr>
<td>5 p.m.</td>
<td>Panel Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:25 p.m.</td>
<td>Closing Remarks</td>
<td>Jennifer Guerriero, PhD</td>
<td><em>Dana-Farber Cancer Institute</em></td>
</tr>
</tbody>
</table>

### Track B: Nonprofit or Government Grants for Independent Investigators

*Chesapeake H*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 p.m.</td>
<td>Welcome and Introductions</td>
<td>Ana Carrizosa Anderson, PhD</td>
<td><em>Harvard Medical School</em></td>
</tr>
</tbody>
</table>
3:05 – 3:35 p.m.  Overview of Non-Profit Sector Funding  
William H. Chambers, PhD – American Cancer Society

3:35 – 4:05 p.m.  Overview of NIH/NCI Grants  
Susan McCarthy, PhD – National Cancer Institutes, Division of Cancer Biology

4:05 – 4:20 p.m.  Break

4:20 – 5 p.m.  Guided Tour of NIH Peer Review Process  
Denise R. Shaw, PhD – National Institutes of Health, Center for Scientific Review

5 – 5:25 p.m.  Panel Discussion

5:25 – 5:30 p.m.  Closing Remarks  
Ana Carrizosa Anderson, PhD – Harvard Medical School
32nd Annual Meeting

**Friday, November 10, 2017**

7 a.m. – 8 a.m.  Breakfast  
*Maryland and Cherry Blossom Foyers*

7 a.m. – 6:30 p.m.  Registration  
*Cherry Blossom Foyer*

8 – 8:05 a.m.  Presidential Welcome  
Lisa H. Butterfield, PhD – *University of Pittsburgh*

**Update Session**

**Session 100: National Cancer Institute Update**  
*Maryland Ballroom*

8:05 – 8:20 a.m.  National Cancer Institute Update  
T. Kevan Howcroft, PhD – *National Cancer Institute*

8:20 – 8:35 a.m.  2016 NCI Immunotherapy Fellowship Update  
Julius Strauss, MD – *National Cancer Institute*

**Plenary Session**

**Session 101: Keynote Address: The CAR T Revolution in Leukemia**  
*Maryland Ballroom*

8:35 – 8:40 a.m.  Welcome and Introductions  
Lisa H. Butterfield, PhD – *University of Pittsburgh*

8:40 – 9:20 a.m.  The CAR T Revolution in Leukemia  
Stephan Grupp, MD, PhD – *University of Pennsylvania*

9:20 – 9:25 a.m.  Q&A and Closing Remarks  
Stephan Grupp, MD, PhD – *University of Pennsylvania*

**Plenary Session**

**Session 102: Science Behind the Therapy: Mechanisms of Efficacy & Toxicity**  
*Maryland Ballroom*

Co-Chairs:  
Kevan Herold, MD – *Yale University*  
Arlene H. Sharpe, MD, PhD – *Harvard Medical School*

9:25 – 9:35 a.m.  Introduction  
Arlene H. Sharpe, MD, PhD – *Harvard Medical School*

9:35 – 9:55 a.m.  Clinical Overview of Checkpoint Inhibitors  
Jeffrey A. Sosman, MD – *Northwestern University*

9:55 – 10:15 a.m.  Autoimmune Endocrinopathies  
Kevan Herold, MD – *Yale University*

10:15 – 10:30 a.m.  Break  
*Maryland Foyers*
10:30 – 10:50 a.m.  
**Colitis**  
Michael Dougan, MD, PhD – *Massachusetts General Hospital*

10:50 – 11:10 a.m.  
**Cardiovascular Autoimmunity**  
Andrew Lichtman, MD, PhD – *Brigham and Women’s Hospital*

11:10 – 11:30 a.m.  
**Severe Neurotoxicity in the Phase 2 Trial of JCAR015 in Adult B-ALL (ROCKET Study): Analyses of Patient, Protocol and Product Attributes**  
Mark J. Gilbert, MD – *Juno Therapeutics, Inc.*

11:30 – 11:45 a.m.  
**Antibody-Mediated Neutralization of Soluble MIC Significantly Enhances Response to CTLA4 Blockade and Reduces Therapy-Induced Colitis**  
Jennifer Wu, PhD – *Northwestern University*

11:45 a.m. – Noon  
**Diversity and Composition of the Gut Microbiome Influences Responses to Anti-PD1-Therapy through Beneficial Changes in Innate and Adaptive Immunity**  
Vancheswaran Gopalakrishnan, PhD – *The University of Texas MD Anderson Cancer Center*

**Late-Breaking Abstract Session I**  
**Session 103: Oral Abstract Presentations**  
*Maryland Ballroom*

Noon – 12:15 p.m.  
**Interim Safety Analysis of Cancer Immunotherapy Trials Network – 12 (CITN-12): A Phase 1 Study of Pembrolizumab in Patients with HIV and Relapsed, Refractory or Disseminated Malignancies**  
Thomas S. Uldrick, MD, MD – *National Cancer Institute*

12:15 – 12:30 p.m.  
**Nivolumab in Mismatch-Repair Deficient (MMR-d) Cancers: NCI-MATCH Trial (Molecular Analysis for Therapy Choice) Arm Z1D Preliminary Results**  
Nilofer Azad, MD – *Johns Hopkins University*

12:30 – 2 p.m.  
**Lunch, Poster Viewing*, Exhibits**  
*Odd Poster Number Authors Present*

12:45 – 1:45 p.m.  
**Oral Poster Sessions**  
*Back of Prince George’s Exhibition Hall DE*

**Concurrent Sessions**  
**Concurrent Session 104: Clinical Trials: New Agents**  
*Maryland Ballroom*

1:45 – 2 p.m.  
**First in Human Study with the CD40 Agonistic Monoclonal Antibody APX005M in Subjects with Solid Tumors**  
Robert Vonderheide, MD, PhD – *Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania*

2 – 2:15 p.m.  
**First-in-Human Study with Intratumoral Administration of a CD40 Agonistic Antibody: Preliminary Results with ADC-1013/JNJ-64457107 in Advanced Solid Malignancies**  
Peter Ellmark, PhD – *Alligator Bioscience*
2:15 – 2:30 p.m.  Monotherapy Dose Escalation Clinical and Translational Data from First-in-Human Study in Advanced Solid Tumors of IPI-549, an Oral, Selective, PI3K-Gamma Inhibitor Targeting Tumor Macrophages
David Hong, MD – University of Texas MD Anderson Cancer Center

2:30 – 2:45 p.m.  Phase 1 Trial of CA-170, a First-in-Class, Orally Available, Small Molecule Immune Checkpoint Inhibitor (ICI) Dually Targeting PD-L1 and VISTA, in Patients with Advanced Solid Tumors or Lymphomas
Yung Jue Bang, PhD, MD – Seoul National University Hospital

2:45 – 3 p.m.  Phase 1 Trial of IL-15 Superagonist ALT-803 (IL-15N72D:IL-15RαSu/IgG1 Fc complex) in Advanced Solid Tumors: Tolerability and Correlates of Activity
Kim Margolin, MD, FACP – City of Hope

3 – 3:15 p.m.  Initial Results from Phase 1 Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with NSCLC Refractory or Resistant to Prior Anti–PD-1/Anti–PD-L1 Agents
James L. Gulley, MD, PhD, FACP – National Cancer Institute

3:15 – 3:30 p.m.  Phase 1 Study of E7046, a Novel PGE2 Receptor Type 4 Inhibitor, in Patients with Advanced Solid Tumors with High Myeloid Infiltrate: Effects on Myeloid- and T-Lymphoid Cell-Mediated Immunosuppression
Aurelien Marabelle, MD, PhD – Gustave Roussy Institute

Concurrent Session 105: Building Personalized Vaccines and Technologies for Hematologic Malignancies and Solid Tumors
Cherry Blossom Ballroom
Co-Chairs:
Matthew M. Gubin, PhD – Washington University School of Medicine
Catherine J. Wu, MD – Dana-Farber Cancer Institute

2 – 2:05 p.m.  Introduction
Matthew M. Gubin, PhD – Washington University School of Medicine

2:05 – 2:25 p.m.  Preclinical & Mouse Models
Matthew M. Gubin, PhD – Washington University School of Medicine

2:25 – 2:45 p.m.  Tumor Vaccines in AML
David E. Avigan, MD – Beth Israel Deaconess Medical Center

2:45 – 3:05 p.m.  Improvement in Epitope Discovery
Catherine J. Wu, MD – Dana-Farber Cancer Institute

3:05 – 3:20 p.m.  Predictive Biomarkers for Response to Anti-CTLA-4 and Anti-PD-1 Immunotherapy in Melanoma Patients
Priyanka Subrahmanyam, PhD – Stanford University

Plenary Session
Session 106: High Impact Clinical Trial Results
Maryland Ballroom
Chair: Mario Sznol, MD – Yale School of Medicine

3:30 – 3:50 p.m.  Pooled 3-Year Overall Survival Data from Phase II and Phase III Trials of Nivolumab (NIVO) Combined with Ipilimumab (IPI) in Advanced Melanoma
F. Stephen Hodi, MD – Dana-Farber Cancer Institute
3:50 – 4:05 p.m.  Nivolumab + Ipilimumab (N+I) vs Sunitinib (S) for Treatment-Naïve Advanced or Metastatic Renal Cell Carcinoma (aRCC): Results From CheckMate 214, including Overall Survival by Subgroups  
Robert J. Motzer, MD – Memorial Sloan Kettering Cancer Center

4:05 – 4:20 p.m.  Immune and Tumor Responses to Human IL-10 (AM0010, Pegilodecakin) Alone or in Combination with Immune Checkpoint Blockade  
Martin Oft, MD – ARMO BioScience

4:20 – 4:35 p.m.  A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients (pts) with Advanced Solid Tumors  
Glen J. Weiss, MD – Western Regional Medical Center Inc.

4:35 – 4:50 p.m.  Expert Discussant  
Samir N. Khleif, MD – Georgia Cancer Center

4:50 – 5:05 p.m.  Break  
Prince George’s Exhibition Hall DE

Concurrent Sessions

Concurrent Session 107: Oncolytic Viruses and Intratumoral Therapies  
Cherry Blossom Ballroom

Co-Chairs:  
Howard L. Kaufman, MD, FACS – Replimune Group Inc.  
Samuel Rabkin, PhD – Massachusetts General Hospital

5:05 – 5:10 p.m.  Introduction  
Howard L. Kaufman, MD, FACS – Replimune Group Inc.

5:10 – 5:30 p.m.  Oncolytic Viruses in Combination Immunotherapy Approaches  
Howard L. Kaufman, MD, FACS – Replimune Group Inc.

5:30 – 5:50 p.m.  Oncolytic Herpes Simplex Virus Immunovirotherapy for Glioblastoma  
Samuel Rabkin, PhD – Massachusetts General Hospital

5:50 – 6:10 p.m.  Oncolytic Virus Clinical Data  
Brian D. Lichty, PhD – McMaster University

6:10 – 6:25 p.m.  Preclinical Characterization of a Novel STING Agonist, MK-1454  
Saso Cemerski, PhD – Merck Research Laboratories

6:25 – 6:30 p.m.  Closing Remarks  
Samuel Rabkin, PhD – Massachusetts General Hospital

Concurrent Session 108: Energizing Immune Cell Metabolism in Cancer  
Maryland Ballroom

Co-Chairs:  
Susan M. Kaech, PhD – Yale University  
Nicholas P. Restifo, MD – National Cancer Institute

5:05 – 5:25 p.m.  Anti-Tumor T cells: You Are What You Eat  
Susan M. Kaech, PhD – Yale University

5:25 – 5:45 p.m.  Metabolic Control of T cell Epigenetics  
Nicholas P. Restifo, MD – National Cancer Institute

5:45 – 6:05 p.m.  Metabolic Changes in Tumor Microenvironment  
Greg M. Delgoffe, PhD – University of Pittsburgh
6:05 – 6:20 p.m.  
Re-Educing Macrophage through Glutamine Metabolism-Mediated Metabolic and Epigenetic Reprogramming  
Ping-Chih Ho, PhD – University of Lausanne

6:20 – 6:35 p.m.  
Lactic Acid as a Mediator of Metabolic Symbiosis Between Regulatory T cells and the Tumor Microenvironment  
McLane Watson, BS – University of Pittsburgh

6:30 – 8 p.m.  
Poster Reception  
Prince George’s Exhibition Hall DE

8 – 9 p.m.  
Presidential Reception and Membership Business Meeting  
Cherry Blossom Ballroom

Saturday, November 11, 2017

7 – 8 a.m.  
Breakfast  
Maryland and Cherry Blossom Foyers

7 a.m. – 6 p.m.  
Registration  
Cherry Blossom Foyer

8 – 8:05 a.m.  
Organizer Welcome  
Charles G. Drake, MD, PhD – Columbia University Medical Center

Update Session
Session 200: Cancer Immunotherapy Trials Network (CITN) Update  
Maryland Ballroom

8:05 – 8:35 a.m.  
Cancer Immunotherapy Trials Network (CITN)  
Martin A. Cheever, MD – Fred Hutchinson Cancer Research Center

Plenary Session
Session 201: Richard V. Smalley, MD Memorial Lectureship  
Maryland Ballroom

8:35 – 8:40 a.m.  
Introduction  
Lisa H. Butterfield, PhD – University of Pittsburgh

8:40 – 9:20 a.m.  
Activation of Innate and Adaptive Immunity as an In Situ Cancer Vaccine  
Paul M. Sondel, MD, PhD – University of Wisconsin, Madison

9:20 – 9:25 a.m.  
Question & Answer  
Paul M. Sondel, MD, PhD – University of Wisconsin, Madison

Plenary Session
Session 202: Mechanisms of Acquired Resistance to Immunotherapies  
Maryland Ballroom
Co-Chairs:  
Katerina Politi, PhD – Yale School of Medicine  
Antoni Ribas, MD, PhD – University of California, Los Angeles

9:25 – 9:30 a.m.  
Introduction  
Katerina Politi, PhD – Yale School of Medicine

9:30 – 9:55 a.m.  
Acquired Resistance Checkpoint Inhibitors in Lung Cancer  
Katerina Politi, PhD – Yale School of Medicine
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:55 – 10:20 a.m.</td>
<td>Acquired Resistance to PD-1 Blockade in Melanoma</td>
<td>Antoni Ribas, MD, PhD – University of California, Los Angeles</td>
<td></td>
</tr>
<tr>
<td>10:20 – 10:45 a.m.</td>
<td>Break</td>
<td>Prince George’s Exhibition Hall DE</td>
<td></td>
</tr>
<tr>
<td>10:45 – 11:10 a.m.</td>
<td>Acquired Resistance in Melanoma</td>
<td>Annette Paschen, MD – University Hospital Essen</td>
<td></td>
</tr>
<tr>
<td>11:10 – 11:25 a.m.</td>
<td>Single cell RNA Sequencing Reveals Mechanisms of Merkel Cell Carcinoma</td>
<td>Kelly Paulson, PhD, MD - Fred Hutchinson Cancer Research Center</td>
<td></td>
</tr>
<tr>
<td>11:25 – 11:40 a.m.</td>
<td>A Dual and Opposing Role for Tumor Intrinsic Type-II Interferon Sensing</td>
<td>Jason Williams, BS - University of Chicago</td>
<td></td>
</tr>
<tr>
<td>11:40 – 11:55 a.m.</td>
<td>Functional Correlation of Increased Tumor Intrinsic Glycolytic Activity</td>
<td>Weiyi Peng, PhD, MD - The University of Texas MD Anderson Cancer Center</td>
<td></td>
</tr>
<tr>
<td>11:55 a.m. – Noon</td>
<td>Closing Remarks</td>
<td>Antoni Ribas, MD, PhD – University of California, Los Angeles</td>
<td></td>
</tr>
</tbody>
</table>

**Late-Breaking Abstract Session**

**Session 203: Oral Abstract Presentations**

*Maryland Ballroom*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noon – 12:15 p.m.</td>
<td>Preliminary Antitumor and Immunomodulatory Activity of BMS-986205, an</td>
<td>Jason J. Luke, MD – University of Chicago Medical Center</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Optimized Indoleamine 2,3-dioxygenase 1 (IDO1) Inhibitor, in Combination with Nivolumab in Patients with Advanced Cancers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15 – 12:30 p.m.</td>
<td>The Transcription Factor Myb Enhances CD8+ T cell Stemness and Polyfunctionality to Promote Curative Antitumor Immunity</td>
<td>Sanjivan Gautam, PhD – National Cancer Institute</td>
<td></td>
</tr>
<tr>
<td>12:30 – 2 p.m.</td>
<td>Lunch, Poster Viewing,* Exhibits</td>
<td>Prince George’s Exhibition Hall DE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>*Even Poster Number Authors Present</td>
<td></td>
</tr>
<tr>
<td>12:45 – 1:45 p.m.</td>
<td>Oral Poster Session</td>
<td>Back of Prince George’s Exhibition Hall DE</td>
<td></td>
</tr>
</tbody>
</table>

**Concurrent Sessions**

**Concurrent Session 204: Presidential Session**

*Maryland Ballroom C*

*Chair:* Lisa H. Butterfield, PhD – University of Pittsburgh

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 – 2:05 p.m.</td>
<td>Introduction</td>
<td>Lisa H. Butterfield, PhD – University of Pittsburgh</td>
<td></td>
</tr>
<tr>
<td>2:05 – 2:20 p.m.</td>
<td>Identification of Unique Neoantigen Qualities in Long-Term Pancreatic Cancer Survivors</td>
<td>Vinod Balachandran, MD – Memorial Sloan Kettering Cancer Center</td>
<td></td>
</tr>
</tbody>
</table>
2:20 – 2:35 p.m. **Neoadjuvant Nivolumab versus Combination Ipilimumab and Nivolumab followed by Adjuvant Nivolumab in Patients with Resectable Stage III and Oligometastatic Stage IV Melanoma: Preliminary Findings**
Sangeetha M. Reddy, MD, MSc – *The University of Texas MD Anderson Cancer Center*

2:35 – 2:45 p.m. **Expert Discussant**
Charles Drake, MD, PhD – *Columbia University Medical Center*

2:45 – 3 p.m. **Cross-Dressed Dendritic Cells Drive Anti-Tumor Immunity**
Brendan MacNabb, BS – *The University of Chicago*

3 – 3:15 p.m. **Metabolic Adaptations Establish Immunotherapy Resistance in Melanoma**
Ashvin R. Jaiswal, DPharm, MS, PhD — *UT MD Anderson Cancer Center*

3:15 – 3:25 p.m. **Expert Discussant**
Susan M. Kaech, PhD – *Yale University*

**Concurrent Session 205: Tumor Immunology 101 (Physician/Nurse/Pharmacist Track)**
Cherry Blossom Ballroom
Co-Chairs:
Laura S. Wood, RN, MSN, OCN – *Cleveland Clinic Taussig Cancer Center*
Krista M. Rubin, MS, FNP-BC – *Massachusetts General Hospital*

2 – 2:05 p.m. **Introduction**
Laura S. Wood, RN, MSN, OCN – *Cleveland Clinic Taussig Cancer Center*

2:05 – 2:30 p.m. **Immunology 101 for the Non-Immunologist**
Yvonne Saenger, MD – *Columbia University Medical Center*

2:30 – 2:55 p.m. **Basic Principles of Tumor Immunotherapy**
Michael K. Wong, MD, PhD, FRCP – *MD Anderson Cancer Center*

2:55 – 3:20 p.m. **Drug Classifications and Mechanisms of Action**
Lisa Cordes, PharmD, BCACP, BCOP – *National Cancer Institute/National Institutes of Health*

3:20 – 3:25 p.m. **Closing Remarks**
Krista M. Rubin, MS, FNP-BC – *Massachusetts General Hospital*

**Concurrent Session 206: Economics of Immunotherapies and Immunotherapy Combinations**
Maryland Ballroom C
Co-Chairs:
Michael B. Atkins, MD – *Georgetown-Lombard Comprehensive Cancer Center*
Bruce Levine, PhD – *Abramson Cancer Center*

3:25 – 3:27 p.m. **Introduction**
Michael B. Atkins, MD – *Georgetown Lombard Comprehensive Cancer Center*

3:27 – 3:42 p.m. **Report on Economics of Checkpoint Inhibitors in Melanoma**
Ahmad Tarhini, MD, PhD – *University of Pittsburgh Cancer Institute*

3:42 – 3:57 p.m. **Report on Economics of Adoptive Cell Therapy**
Richard Maziarcz, MD – *Oregon Health & Science University*

3:57 – 4 p.m. **Q&A and Closing Remarks**
4 – 4:15 p.m.  
**Break**

**Concurrent Session 207: Clinical Trials: Novel Combinations**  
**Room: Maryland Ballroom A**

3:30 – 3:45 p.m.  
**A Phase 1/2 Study of CB-839, a First-in-Class Glutaminase Inhibitor, Combined with Nivolumab in Patients with Advanced Melanoma (MEL), Renal Cell Carcinoma (RCC), or Non-Small Cell Lung Cancer (NSCLC)**  
Funda Meric-Bernstam, MD – The University of Texas MD Anderson Cancer Center

3:45 – 4 p.m.  
**ENCORE-601: Phase 1b/2 Study of Entinostat (ENT) in Combination with Pembrolizumab (PEMBRO) in Patients with Non-Small Cell Lung Cancer (NSCLC)**  
Leena Gandhi, MD, PhD – NYU Langone Medical Center

4 – 4:15 p.m.  
**OX40 T cell Costimulatory Agonist BMS-986178 Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors: Initial Phase 1 Results**  
Anthony J. Olszanski, MD – Fox Chase Cancer Center

4:15 – 4:30 p.m.  
**Early FDG-PET Response Correlates with Dose and Efficacy in Patients with Microsatellite Stable mCRC Treated with Carcinoembryonic Antigen T cell Bispecific (CEA-TCB) Antibody Plus Atezolizumab**  
Jose Saro, MD – Roche Innovation Center Zurich

4:30 – 4:45 p.m.  
**First-in-Human Phase 1 Dose Escalation and Expansion of a Novel Combination, Anti-CSF-1 Receptor (Cabiralizumab) Plus Anti-PD-1 (Nivolumab), in Patients with Advanced Solid Tumors**  
Zev Wainberg, MD – UCLA School of Medicine

4:45 – 5 p.m.  
**TLR9 Agonist Harnesses Innate Immunity to Drive Tumor-Infiltrating T cell Expansion in Distant Lesions in a Phase 1/2 Study of Intratumoral IMO-2125+ipilimumab in Anti-PD1 Refractory Melanoma Patients**  
Cara Haymaker, PhD – University of Texas MD Anderson Cancer Center

5 – 5:15 p.m.  
**Pivot-02: Preliminary Safety, Efficacy and Biomarker Results from the Phase 1/2 Study of CD-122-Biased Agonist NKTR-214 Plus Nivolumab in Patients with Locally Advanced/ Metastatic Solid Tumors**  
Adi Diab, MD – The University of Texas MD Anderson Cancer Center

5:15 – 5:30 p.m.  
**DNA Vaccine with PD-1 Blockade Elicits Anti-Tumor Responses in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC)**  
Douglas McNeel, MD, PhD – University of Wisconsin

5:30 – 5:45 p.m.  
**A Dendritic cell Targeting NY-ESO-1 Vaccine Significantly Augments Early and Durable Immune Responses in Melanoma Patients Pretreated with Human Flt-3 Ligand**  
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at The Mount Sinai Medical Center

5:45 – 6 p.m.  
**Clinical Activity of Adenosine 2A Receptor (A2AR) Inhibitor CPI-444 is Associated with Tumor Expression of Adenosine Pathway Genes and Tumor Immune Modulation**  
Jason Luke, MD – University of Chicago Medical Center
### Concurrent Session 208: Clinical Management (Physician/Nurse/Pharmacist Track)

**Cherry Blossom Ballroom**

**Conference Chair:**
Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Center
Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital

#### 3:40 – 3:45 p.m.
**Introduction**
Laura S. Wood, RN, MSN, OCN - Cleveland Clinic Taussig Cancer Center

#### 3:45 – 4:15 p.m.
**General Concepts of Toxicity Management**
Michael Postow, MD – Memorial Sloan Kettering Cancer Center

#### 4:15 – 4:35 p.m.
**Pharmacological Management of irAEs**
Nathan Dahl, Pharm D, R.Ph - Mayo Clinic

#### 4:35 – 5 p.m.
**Panel Discussion: Management of Complex Adverse Events**
*Moderator:* Laura S. Wood, RN, MSN, OCN - Cleveland Clinic Taussig Cancer Center
*Panelists:*
Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital
Nathan Dahl, Pharm D, R.Ph – Mayo Clinic
Michael Postow, MD – Memorial Sloan Kettering Cancer Center

#### 5 – 5:15 p.m.
**Variance from Evidence-Based Management of Immune-Related Adverse Events Among Healthcare Providers: Analysis of an Online Management Decision Tool**
Krista Marcello, BA – Clinical Care Options, LLC

#### 5:15 – 5:30 p.m.
**Audience Q&A**
*Moderator:*
Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital

---

### Concurrent Session 209: Emerging Models & Imaging

**Maryland Ballroom C**

**Conference Chair:**
Daniel Thorek, PhD – Johns Hopkins University School of Medicine
Ronald N. Germain, MD, PhD – National Institute of Allergy and Infectious Diseases, National Institute of Health

#### 4:15 – 4:20 p.m.
**Introduction**
Ronald N. Germain, MD, PhD – National Institute of Allergy and Infectious Diseases, National Institute of Health

#### 4:20 – 4:40 p.m.
**Imaging Immunity - Developing a Spatiotemporal Understanding of Host Defense and Tumor Immunity**
Ronald N. Germain, MD, PhD – National Institute of Allergy and Infectious Diseases, National Institute of Health

#### 4:40 – 5 p.m.
**Molecular Imaging of Checkpoint Blockade**
Daniel Thorek, PhD – Johns Hopkins University School of Medicine

#### 5:05 – 5:20 p.m.
**Multiplex Three-Dimensional Optical Mapping of Tumor Immune Microenvironment**
Steve Seung-Young Lee, PhD – University of Chicago

#### 5:20 – 5:35 p.m.
**Combining Immunophenomics with a Gene Expression Panel for Improved Prostate Cancer Recurrence Prediction**
Nathalie Harder, PhD – Definiens AG

#### 5:35 – 5:40 p.m.
**Closing Remarks**
Daniel Thorek, PhD – Johns Hopkins University School of Medicine
Award Ceremony
Maryland Ballroom C
6 – 6:30 p.m. Award Ceremony
Lisa H. Butterfield, PhD – University of Pittsburgh
6:30 – 8 p.m. Poster Reception
Prince George’s Exhibition Hall DE
8:30 – 11:30 p.m. The CheckPoints Party
Maryland Ballroom

Sunday, November 12, 2017
7 – 8 a.m. Breakfast
Cherry Blossom Foyer
7 – 10 a.m. Registration
Cherry Blossom Foyer
8 – 8:05 a.m. Organizer Welcome
Marcela V. Maus, MD, PhD – Massachusetts General Hospital

Plenary Session
Session 300: Genetically Modified Cell Therapy
Organized in collaboration with the American Society for Blood and Marrow Transplantation (ASBMT)
Cherry Blossom Ballroom
Co-Chairs:
Marcela V. Maus, MD, PhD – Massachusetts General Hospital
Helen E. Heslop, MD – Baylor College of Medicine
Carl H. June, MD – University of Pennsylvania
8:05 – 8:30 a.m. Gene Edited CAR T cells
Martin Pule, PhD – University College London
8:30 – 8:55 a.m. Updates in CAR T cells
Crystal L. Mackall, MD – Stanford University
8:55 – 9:20 a.m. Genetically Modified T Cells for Solid Tumors
Stephen M. Gottschalk, MD – St. Jude Children’s Research Hospital
9:20 – 9:45 a.m. Late-Breaking: CD19 CAR Enter the Mainstream
Jennifer Brogdon – Novartis Institute of Biomedical Research
9:45 – 10 a.m. Transcriptional Approach to Understanding the Role of Tonic Signaling and Co-Stimulation in CAR T cells
Angela Boroughs, BS – Massachusetts General Hospital, Harvard University
10 – 10:15 a.m. Gamma Secretase Inhibition Increases Recognition of Multiple Myeloma by BCMA-Specific Chimeric Antigen Receptor Modified T cells
Margot Pont, PhD – Fred Hutchinson Cancer Research Center
Hot Topic Symposium

Session 301: Advancing the Field: Can Physics and Mathematics Impact the Development of Tumor Immunotherapy?

Organized in collaboration with Stand Up To Cancer (SU2C)
Cherry Blossom Ballroom

Co-Chairs:
Howard Kaufman, MD, FACS – Replimune Group Inc.
Herbert Levine, PhD – Rice University

10:30 – 10:35 a.m. Welcome and Introductions
Howard Kaufman, MD, FACS – Replimune Group, Inc.

10:35 – 10:55 a.m. Overview of the Immunotherapy Field
Francesco M. Marincola, MD – AbbVie Inc.

10:55 – 11:15 a.m. Emerging Topics
Thomas F. Gajewski, MD, PhD – University of Chicago

11:15 – 11:35 a.m. Challenges in Clinical Development
Michael Postow, MD – Memorial Sloan Kettering Cancer Center

11:35 – 11:55 a.m. Systems of Biology Modeling of the Immune System
Doron Levy, PhD – University of Maryland

11:55 a.m. – 12:15 p.m. T cell Repertoire
Curtis Callan, PhD – Princeton University

12:15 – 12:35 p.m. Modeling the Fitness Costs of Neoantigens
Benjamin Greenbaum, PhD – The Tisch Cancer Institute

12:35 – 1 p.m. Panel Discussion
Moderators:
Howard Kaufman, MD, FACS – Replimune Group, Inc.
Herbert Levine, PhD – Rice University